Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation

[1]  M. Rashidi,et al.  Inhibition of Survivin Restores the Sensitivity of Breast Cancer Cells to Docetaxel and Vinblastine , 2014, Applied Biochemistry and Biotechnology.

[2]  F. Tsai,et al.  Survivin – biology and potential as a therapeutic target in oncology , 2013, OncoTargets and therapy.

[3]  D. Noh,et al.  HER2 stabilizes survivin while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage. , 2013, The Biochemical journal.

[4]  C. Papadimitriou,et al.  Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. , 2012, Cancer treatment reviews.

[5]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[6]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[7]  S. Rodenhuis,et al.  Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics , 2012, Breast Cancer Research and Treatment.

[8]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[9]  Ling Wang,et al.  The role of survivin in diagnosis, prognosis and treatment of breast cancer. , 2011, Journal of thoracic disease.

[10]  C. Streuli,et al.  Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer , 2009, Breast Cancer Research.

[11]  M. Andreeff,et al.  Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance , 2009, Clinical Cancer Research.

[12]  S. Baird,et al.  IAP-targeted therapies for cancer , 2008, Oncogene.

[13]  A. Schönthal,et al.  Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. , 2008, The American journal of pathology.

[14]  Hao Song,et al.  Upregulation of survivin by leptin/STAT3 signaling in MCF-7 cells. , 2008, Biochemical and biophysical research communications.

[15]  Aisha Siddiqa,et al.  Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways , 2008, BMC Cancer.

[16]  J. Meléndez-Zajgla,et al.  Regulation of mitochondrial Smac/DIABLO-selective release by survivin , 2007, Oncogene.

[17]  W. Fairbrother,et al.  The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer , 2007, Clinical Cancer Research.

[18]  R. Korneluk,et al.  The inhibitors of apoptosis (IAPs) as cancer targets , 2007, Apoptosis.

[19]  Yi Huang,et al.  Estrogen Receptor α Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death , 2007 .

[20]  R. Walker,et al.  Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients , 2007, British Journal of Cancer.

[21]  Yi Huang,et al.  Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. , 2007, Cancer research.

[22]  S. Byun,et al.  Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. , 2007, Urology.

[23]  D. Altieri.  The case for survivin as a regulator of microtubule dynamics and cell-death decisions. , 2006, Current opinion in cell biology.

[24]  F. Holmes,et al.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[26]  M. A. Hardwicke,et al.  Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. , 2006, Cancer research.

[27]  T. Ohmura,et al.  Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. , 2005, Cancer research.

[28]  Y. Pommier,et al.  Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. , 2003, Cancer research.

[29]  R. Kalb,et al.  Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway* , 2000, The Journal of Biological Chemistry.

[30]  M. Hung,et al.  Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. , 1996, Oncogene.

[31]  W. Dalton.  Mechanisms of drug resistance in breast cancer. , 1990, Seminars in oncology.